AzTrials
AzTrials

I-gelNCT03086941

Blind Versus Fiberoptic Intubation Through I-GEL

A study testing I-gel in people with I-gel, run by Cairo University at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Aim of the work To compare between use of I-gel as a conduit for blind intubation and as a conduit for fiberoptic guided intubation in children and also aim to validate the use of I-gel as conduit for blind intubation in absence of fiberoptic or lack of experience of its use. Read more about this study

Who is it for?
Ages 2 to 6 years
Conditions the study is for
I-gel
What is being tested?
I-gel
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
88 participants
Where
1 siteEgypt
Study dates
1 Sep 2016to 20 Dec 2017
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 2 to 6 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • ASA physical status I-II
  • Age (2-6)

Who cannot join

  • Known difficulty of intubation. (Airway assessment clinically for presence of retrognathia, small mandibular cavity, limited neck or mandibular mobility and presence of syndromes associated with facial abnormalities e.g Pierre Robin sequence, Treacher Collins, Hurler's Hunter's syndrome (mucopolysaccharidoses), Beckwith-Wiedemann syndrome and Down's syndrome.)
  • Emergency surgery.
  • Risk of aspiration (e.g; full stomach, GERD, CHPS).
  • Respiratory tract infections.
  • Children not fitted with I-Gel.

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Children Hospital of Cairo University

    Cairo, 11956

Other trials in Egypt

About this study

Official title: The Use of Supraglottic I-Gel Airway as a Conduit for Fiberoptic Guided and Blind Intubation in Children

Aim of the work

To compare between use of I-gel as a conduit for blind intubation and as a conduit for fiberoptic guided intubation in children and also aim to validate the use of I-gel as conduit for blind intubation in absence of fiberoptic or lack of experience of its use.

Objectives:

  • To validate I-gel use as blind intubating conduit in children.
  • To Estimate the duration of blind intubation using I-gel and duration of fiberoptic guided intubation through I-gel.

Ethical Considerations

The study protocol will be approved by the Research Ethics Committee.

Read the detailed description

Introduction:

A supraglottic airway device is designed to maintain a clear airway while sitting above, and creating a seal around the larynx. It may be used in elective surgery, as an airway rescue device in failed tracheal intubation, as a conduit for tracheal intubation, or in emergencies such as cardiorespiratory arrest, both in and out of hospital.

'First-generation'supraglottic airway devices are simple airway tubes such as the laryngeal mask airway (LMA) Classic. 'Second generation' devices contain suction ports and integral bite blocks, these include the LMA Proseal and the i-gel.

The I-gel is the innovate second generation supraglottic airway and it is considered the first major development since LMA. The I-gel has changed the face of airway management and is now widely used in anesthesia and resuscitation across the globe. It is made from a medical grade thermoplastic elastomer and it is designed to create a non-inflatable, anatomical seal of the pharyngeal, laryngeal and perilaryngeal structures.

Pediatrics are not small adults, there are a number of anatomical differences which make airway management difficult than adults. Predicatably, these differences are most pronounced at birth and the most unfamiliar(non-adult like) airway is encountered in neonates and infants under 1 year of age.

Aim of the work

To compare between use of I-gel as a conduit for blind intubation and as a conduit for fiberoptic guided intubation in children and also aim to validate the use of I-gel as conduit for blind intubation in absence of fiberoptic or lack of experience of its use.

Objectives:

  • To validate I-gel use as blind intubating conduit in children.
  • To Estimate the duration of blind intubation using I-gel and duration of fiberoptic guided intubation through I-gel.

Ethical Considerations

The study protocol will be approved by the Research Ethics Committee.

Methodology

  1. Study design

Prospective randomized controlled trial (non inferiority design)

II. Study setting and location

The study will be conducted in Children Hospital of Cairo University.

III. Study population

This Study will be conducted on 88 children aged from one to ten years presented for elective surgical procedure at Children Hospital of Cairo University. Patient will be divided into two equal groups; group C control group (n=44) and group B (blind) (n=44).

  1. Study Procedures
  2. Randomization (in RCT only) Once enrolled in the study, patients will be randomly assigned into two groups; fiberoptic guided (control) group (Group C: n= 44), blind group (Group B: n=44). Randomization will be done using computer generated number and concealed using sequentially numbered, sealed opaque envelope.
  3. Study Protocol Randomization will be done by computer generated numbers and concealed by serially numbered, opague and sealed envelopes. The details of the series will be unknown to the investigators and the group assignment will be kept in asset of sealed envelopes each bearing only the case number on the outside. Prior to surgery the appropriate numbered envelopes will be opened by the nurse, the card inside will determine the patient group. All children will be premedicated with oral midazolam 0.5mg/kg Half hour before procedure and atropine at a dose of 0.02mg/kg (IM). Continuous electrocardiogram (ECG), pulse oximetry, non-invasive arterial blood pressure, and temperature monitoring will be applied and all patients will be induced with inhalational anesthetic using Sevoflurane + oxygen (O2) and I.V line will be inserted. After deepening of the anesthesia, fentanyl 1μg/kg, and muscle relaxant will be given in the form of atracurium 0.5mg/kg. The absence of mydriasis, divergent gaze, haemodynamic or motor response to the jaw thrust manoeuvre will be used as parameters to guide adequate depth of anesthesia(7). Supraglottic I-gel of appropriate size (according to body wight) will be inserted after lubrication with K-Y Lubricating Jelly (Johnson \& Johnson Medical Limited, Gargrave, Skipton, UK). Air way manoeuvres like jaw thrust or head tilt will be used to facilitate insertion. Adequate ventilation will be confirmed by adequate chest expansion and capnography waveform. If ventilation is adequate, the SG I-gel will be secured. In case of inadequate ventilation after I-gel insertion, airway manoeuvres like adjusting head/neck position and changing depth of insertion can be used to improve ventilation.A maximum of three SGA insertion attempts will be allowed then conventional laryngoscopic intubation will be performed. After securing SG I-gel, according to patients group; in group C (control), a paediatric fibrescope will be primed with an appropriate size tracheal tube. The fibrescope will be introduced through I-gel and guide tracheal intubation. After insertion of tube and confirmation of position, the fiberscope will be removed In group B (blind); an appropriate size endotracheal tube will be introduced through I-gel blindly. Only smooth intubation without force together with manoeuvres necessary to correct the position of tracheal tube will be allowed. Only one attempt of blind intubation is allowed to avoid airway injury. Any resistance to first attempt tube insertion will indicate failure of blind tube insertion. In both groups, a second person will stabilise the SG I-gel in the set position in order to prevent unintentional movement during the intubation procedure and removal of I-gel. Tube insertion will be confirmed by capnography, fibrescope and bilateral air entry by auscultation after connection of breathing circuit. To remove the SG I-gel after successful intubation, the breathing circuit will be disconnected, and the I-gel will be withdrawn with the aid of a stylet (stabilizer) in a continuous push-pull movement. If saturation fall below 92%, or if facemask ventilation or ventilation via the SGA begin to fail, this indicate securing airway with conventional intubation
  4. Measurement tools
  • Patients demographic data will be collected; age, gender, weight, height and type of surgery.
  • The success rate and number of attempts of SG I-gel insertion will be recorded and the time taken for insertion from removal of face mask until appearance of end-tidal CO2 on the monitor after connection of the breathing circuit to the SG I-gel.
  • The success rate of first attempt intubation and time taken for tube insertion from start of tube introduction till appearance of appearance of end-tidal CO2 on the monitor after connection of the breathing circuit to the tube will be recorded.
  • Adverse events will be recorded ; suspicion of aspiration or regurgitation, hypoxia, bronchospasm, laryngospasm and coughing. Staining of blood on the SG I-gel will be recorded, as well as dental, tongue or lip trauma.
  • Postoperative dysphagia, sore throat and hoarseness of voice will be recorded.

VI. Study outcomes

  1. Primary outcome
  • The success rate of first attempt intubation
  1. Secondary outcome(s)
  • The success rate of SG I-gel insertion
  • Number of trials of I-gel insertion with maximum three trials.
  • Time taken for I-gel insertion.
  • Time taken for endotracheal tube insertion.
Conditions
I-gel
Being tested
I-gel

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • I-gelDevice

    To compare between use of I-gel as a conduit for blind intubation and as a conduit for fiberoptic guided intubation in children. We also aim to validate the use of I-gel as conduit for blind intubation in absence of fiberoptic or lack of experience of its use.

Study groups in NCT03086941
Study groupRoleWhat they receive
Group B(blibd)Active comparatorgroup B (blind); an appropriate size endotracheal tube will be introduced through I-gel blindly. Only smooth intubation without force together with manoeuvres necessary to correct the position of tracheal tube will be allowed. Only one attempt of blind intubation is allowed to avoid airway injury. Any resistance to first attempt tube insertion will indicate failure of blind tube insertion.
Receives: Device: I-gel
Group C(control)Active comparatorgroup C (control), a paediatric fibrescope will be primed with an appropriate size tracheal tube. The fibrescope will be introduced through I-gel and guide tracheal intubation. After insertion of tube and confirmation of position, the fiberscope will be removed
Receives: Device: I-gel

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The success rate of first attempt intubation

    assessing the success rate of first attempt to insert the endotracheal tube through I-gel either blindly or by a fiberscope

    Measured: The success rate for insertion will be recorded 5 minutes after induction of anesthesia

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Mar 2017
  2. Study start1 Sep 2016
  3. Primary completion1 Nov 2017
  4. Study completion20 Dec 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
88 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03086941
Sponsor's protocol ID
N-60-2016
Status last verified
Dec 2017
First submitted
11 Mar 2017
Last updated
27 Dec 2017
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing I-gel in people with I-gel, run by Cairo University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 27 Dec 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The success rate of first attempt intubation (time frame: The success rate for insertion will be recorded 5 minutes after induction of anesthesia). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Dec 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in